跳至主要内容
临床试验/NCT01201577
NCT01201577已完成1 期

Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals

University of Nottingham1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2009年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
40
试验地点
1
主要终点
Serum QSSM level

研究概览

简要总结

It has recently been discovered that bacteria are able to communicate using specialised molecules known as Quorum Sensing Signalling Molecules (QSSMs). An accumulation of QSSMs in their surrounding environment allow for the bacteria to quantify the size of colonies. At specific colony sizes the concentration of QSSMs reaches a critical threshold leading to the activation of genes that cause an infection. It is by this mechanism that bacteria within a colony coordinate behaviour to activate infectivity when colony sizes are large enough to withstand defensive measures from the host's immune system. A disruption of quorum sensing may reduce the severity of infection and this has led to the development of inhibitors of quorum sensing as a new strategy in antibacterial therapy.

QSSMs are also thought to facilitate infection by other mechanisms and are able to influence the number and function of a specific type of immune cell known as an 'antigen presenting cell'. These cells are pivotal in allowing the immune system to recognise components of bacteria as foreign and thereby mount the appropriate response. It was found that large numbers of these types of cells underwent programmed cell death (cell suicide) in the presence of QSSMs compared to when QSSMs were absent. This mirrors the situation in blood sampled from patients with severe infections where there is a greater proportion of cell deaths among antigen presenting cells than other types of immune cell.

This study aims to establish in healthy volunteers, the mechanisms by which QSSMs affect immune cells and facilitate the spread of infection. Antibiotic administration in humans can alter the environment of the intestine and can lead to an overgrowth of harmful bacteria to potentially cause an infection. Probiotics supplements can prevent bacterial overgrowth and potentially reduce infective complications. The mechanism, which we aim to clarify, may involve changes in both the production of QSSMs and the function of immune cells.

Hypothesis

  1. Antibiotic use alters gut flora, leading to the appearance in the systemic circulation of bacterial QSSMs and changes in immune function of the host.
  2. Probiotics and/or prebiotics have beneficial effects by preserving the normal resident gut flora, thereby, modulating bacterial QSSMs and preserving the immune function of the host.

Aims

The aims of our study are 2 fold:

  1. Firstly, to study the effect of orally administered antibiotic on QSSMs (in faeces and blood) and on innate and adaptive immunity in healthy humans.
  2. Secondly, to study the effect of orally administered combinations of prebiotic, probiotic and antibiotic on QSSMs (in faeces and blood) and on innate and adaptive immunity in healthy humans.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Male volunteers
  • Age 18-55 years
  • Willing to participate and able to give informed consent
  • Alcohol abstinence during study

排除标准

  • Smokers/substance abusers
  • Individuals with diabetes mellitus
  • Oral/Intravenous steroids
  • Allergy to azithromycin
  • Individuals already taking regular medications/probiotics/nutritional supplements
  • Individuals with chronic disease or currently under investigation
  • Individuals with ≤3 bowel movements/week
  • Individuals with ≥2 bowel movements/day

研究组 & 干预措施

Placebo/Probiotic

Active Comparator

干预措施: Bifidobacterium longum BB536 (Dietary Supplement)

Placebo/Probiotic

Active Comparator

干预措施: Azithromycin (Drug)

Placebo/Prebiotic

Active Comparator

干预措施: Active hexose correlated compound (AHCC) (Dietary Supplement)

Placebo/Prebiotic

Active Comparator

干预措施: Azithromycin (Drug)

Prebiotic/Probiotic

Active Comparator

干预措施: Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC) (Dietary Supplement)

Prebiotic/Probiotic

Active Comparator

干预措施: Azithromycin (Drug)

Placebo/Placebo

Placebo Comparator

干预措施: Corn starch placebo capsule (Dietary Supplement)

Placebo/Placebo

Placebo Comparator

干预措施: Azithromycin (Drug)

结局指标

主要结局

Serum QSSM level

时间窗: 14 days

次要结局

  • T cell Th1/Th2 ratio(14 days)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验